Author:
Kuan Feng-Che,Kuo Liang-Tseng,Chen Min-Chi,Yang Cheng-Ta,Shi Chung-Sheng,Teng David,Lee Kuan-Der
Publisher
Springer Science and Business Media LLC
Reference53 articles.
1. Chou TY, Chiu CH, Li LH, Hsiao CY, Tzen CY, Chang KT, Chen YM, Perng RP, Tsai SF, Tsai CM (2005) Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin Cancer Res 11: 3750–3757.
2. Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR, Ward RA, Mellor MJ, Hughes G, Rahi A, Jacobs VN, Red Brewer M, Ichihara E, Sun J, Jin H, Ballard P, Al-Kadhimi K, Rowlinson R, Klinowska T, Richmond GH, Cantarini M, Kim DW, Ranson MR, Pao W (2014) AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 4 (9): 1046–1061.
3. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Controlled Clin Trials 7 (3): 177–188.
4. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315 (7109): 629–634.
5. EURTAC (2013) Highlights of Prescribing Information. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021743s018lbl.pdf accessed on 20 October 2014.
Cited by
93 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献